HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
STMN3
stathmin 3
Chromosome 20 · 20q13.33
NCBI Gene: 50861Ensembl: ENSG00000197457.11HGNC: HGNC:15926UniProt: Q9NZ72
37PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
protein bindingGolgi apparatusprotein domain specific bindingmicrotubule depolymerizationneurodegenerative diseaseprostate carcinomaprostate cancerrenal carcinoma
✦AI Summary

STMN3 (stathmin 3) is a microtubule-destabilizing protein involved in cytoskeletal regulation and nervous system development. It exhibits intrinsic microtubule depolymerization activity and binds tubulin to regulate microtubule polymerization dynamics 1. STMN3 functions in axonal maintenance through membrane association driven by palmitoylation and undergoes regulated degradation via dual leucine zipper kinase (DLK) signaling 1. In cancer biology, STMN3 has emerged as a disease-relevant gene across multiple malignancies. It is differentially expressed in gastric neuroendocrine carcinomas compared to adenocarcinomas 2 and serves as a component of a nine-gene prognostic signature for bladder cancer patient stratification and immunotherapy response prediction 3. In non-small cell lung cancer, nicotine promotes STMN3 expression in an ID1-dependent manner to facilitate cell proliferation, invasion, and migration 4. STMN3 expression is also regulated by RUNX1 in renal cell carcinoma, where it contributes to extracellular matrix remodeling programs 5. Genetically determined variation at the STMN3/RTEL1 locus associates with glioma risk 6, and STMN3 expression in brain tissues shows causal association with glioma susceptibility 7. STMN3 was also identified as a differentially expressed gene in prostate cancer 8. These findings establish STMN3 as a clinically significant biomarker and potential therapeutic target in cancer progression and neuronal pathologies.

Sources cited
1
STMN3 colocalizes with STMN2-containing vesicles and undergoes DLK-dependent regulated degradation; palmitoylation is critical for axon-protective activity
PMID: 37236359
2
STMN3 is differentially expressed between adenocarcinoma and neuroendocrine carcinoma components in gastric MANEC
PMID: 39029904
3
STMN3 is one of nine TMRGs in a novel prognostic signature for bladder cancer predicting survival and immunotherapy response
PMID: 37965307
4
Nicotine induces STMN3 expression in an ID1-dependent manner to promote NSCLC cell proliferation, invasion, and migration
PMID: 25028095
5
STMN3 is affected in RUNX1-regulated transcriptional programs involving extracellular matrix remodeling in renal cell carcinoma
PMID: 32156779
6
Genetic variation at the STMN3/RTEL1 locus (20q13.3) associates with glioma risk through telomere-related mechanisms
PMID: 34477880
7
STMN3 shows causal association with glioma risk through brain tissue-specific eQTL effects
PMID: 33504897
8
STMN3 is identified as a differentially expressed gene biomarker in prostate cancer
PMID: 25491628
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.44Moderate
prostate carcinomaOpen Targets
0.26Weak
prostate cancerOpen Targets
0.24Weak
renal carcinomaOpen Targets
0.23Weak
clear cell renal carcinomaOpen Targets
0.22Weak
uterine fibroidOpen Targets
0.21Weak
cancerOpen Targets
0.19Weak
ulcerative colitisOpen Targets
0.13Weak
melanomaOpen Targets
0.12Weak
upper respiratory tract disorderOpen Targets
0.10Weak
restless legs syndromeOpen Targets
0.09Suggestive
cutaneous melanomaOpen Targets
0.09Suggestive
Eczematoid dermatitisOpen Targets
0.08Suggestive
atopic eczemaOpen Targets
0.08Suggestive
gliomaOpen Targets
0.07Suggestive
Griscelli diseaseOpen Targets
0.07Suggestive
Griscelli disease type 3Open Targets
0.06Suggestive
Griscelli syndrome type 3Open Targets
0.06Suggestive
central nervous system cancerOpen Targets
0.06Suggestive
Blackfan-Diamond anemiaOpen Targets
0.06Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
STMND1Shared pathway43%STMN4Shared pathway43%STMN2Shared pathway33%STMN1Shared pathway25%ATXN10Shared pathway25%NR2F1Shared pathway22%
Tissue Expression6 tissues
Brain
100%
Ovary
35%
Bone Marrow
27%
Lung
9%
Heart
6%
Liver
2%
Gene Interaction Network
Click a node to explore
STMN3STMND1STMN4STMN2STMN1ATXN10NR2F1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9NZ72
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.85LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF1.37 [0.99–1.85]
RankingsWhere STMN3 stands among ~20K protein-coding genes
  • #10,704of 20,598
    Most Researched37
  • #16,822of 17,882
    Most Constrained (LOEUF)1.85
Genes detectedSTMN3
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Distinctive Phenotypic and Microenvironmental Characteristics of Neuroendocrine Carcinoma and Adenocarcinoma Components in Gastric Mixed Adenoneuroendocrine Carcinoma.
PMID: 39029904
Mod Pathol · 2024
1.00
2
Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
PMID: 37965307
Front Immunol · 2023
0.90
3
Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner.
PMID: 25028095
Mol Cancer · 2014
0.80
4
RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome.
PMID: 32156779
Cancer Res · 2020
0.70
5
Relationship between genetically determined telomere length and glioma risk.
PMID: 34477880
Neuro Oncol · 2022
0.60